The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer

Abstract

OBJECTIVE:The aim of this study is to verify the expression of proteins that are controlled by miR-let7c, 100 and 218 using immunohistochemistry in tissue microarray representative of localized and metastasized the lymph nodes and bone prostate cancer.METHODS:To verify the expression of proteins that are controlled by miR-let7c (C-MYC, BUB1, RAS) 100 (SMARCA5, RB) and 218 (LAMB3) and cell proliferation (Ki-67) we used immunohistochemistry and computerized image system ImageJ MacBiophotonics in three tissue microarrays representative of localized prostate cancer and lymph node and bone metastases. miRNA expression was evaluated by qRT-PCR using 60 paraffin blocks to construct the tissue microarray representative of localized disease.RESULTS:RAS expression was increased in localized prostate cancer and bone metastases compared to the lymph nodes (p = 0.017). RB showed an increase in expression from localized prostate cancer to lymph node and bone metastasis (p = 0.036). LAMB3 was highly expressed in localized and lymph node metastases (p<0.001). Cell proliferation evaluated by Ki-67 showed an increase from localized prostate cancer to metastases (p<0.001). We did not found any relationship between C-MYC (p = 0.253), BUB1 (p = 0.649) and SMARCA5 (p = 0.315) protein expression with prognosis or tumor behavior.CONCLUSION:We found that the expression of RAS, RB, LAMB3 and Ki-67 changed in the different stages of prostate cancer. Furthermore, we confirmed the overexpression of the miRNAs let7c, 100 and 218 in localized prostate cancer but failed to show the control of protein expression by the putative controller miRNAs using immunohistochemistry.

Elevated Serum MicroRNA Let-7c in Moyamoya Disease

“…33 Let-7c directly inhibits the expression of Bcl-xl and causes endothelial cell apoptosis. Ras participates in signal transduction networks controlling the cytoskeleton and cell proliferation, differentiation, adhesion, apoptosis, and metastasis.…”

Molecular Biological Factors in the Prediction of Prostate Cancer

“…Так, рецептор 1-го типа специфичен для кроветворных клеток. В клетках, не относящихся к гемопоэти-ческим, например эпителий простаты, передача сигнала выполняется посредством рецепторов 2-го типа [9]. Роль IL-4 в противоопухолевом иммуни-тете противоречива, что подтверждается ингиби-рующим влиянием на рост культуры клеток рака толстой кишки и рака молочной железы.…”

“…Прогности-ческую ценность в отношении биохимического рецидива РПЖ представляют собой Let-7b [61]. Изменение экспрессии профилей miRNA-let7c, miRNA-100 и miRNA-218 может свидетельствовать о прогрессировании первично-локализованного к метастатическому РПЖ [9].…”

Nm23‐H1 inhibits lung cancer bone‐specific metastasis by upregulating miR‐660‐5p targeted SMARCA5

“…The chromosome location that determined for the SMARCA5 gene, 4q31, is within a region where loss of heterozygosity (LOH) is frequently observed in hepatocellular carcinomas . Furthermore, studies indicate that SMARCA5 expression is dysregulated in many human malignant tumors, such as gastric cancer, breast cancer, prostate cancer, and acute leukemia . Also, SMARCA5 gene is a target of miRNA regulation .…”

“…22,23 Furthermore, studies indicate that SMARCA5 expression is dysregulated in many human malignant tumors, such as gastric cancer, breast cancer, prostate cancer, and acute leukemia. [24][25][26][27] Also, SMARCA5 gene is a target of miRNA regulation. 28,29 However, the association between SMARCA5 expression and the formation, progression, and metastasis of lung cancer cells remains unclear.…”